Lipid metabolism-improving reagent
AssigneeMegmilk Snow Brand Co., Ltd.
InventorsAtsushi Serizawa, Daisuke Uetsuji, Satoshi Higurashi, Masanobu Sakono, Nobuhiro Fukuda
Life of this patent
Estimating the term…
Abstract
Our objective is to provide a novel lipid metabolism-improving reagent effective in preventing and treating hyperlipidemia and obesity and to provide this reagent in food, beverages, nutritional supplements, and fodders with the ability to improve lipid metabolism. The whey protein hydrolysate as the active ingredient in the lipid metabolism-improving reagent has a molecular weight distribution of 10 kDa or less, with the main peak between 200 Da to 3 kDa, average peptide chain length (APL) of 2-8, free amino acid content of 20% or less, antigenicity of 1/10,000 or less compared with that of β-lactoglobulin.
Claims18
Lipid metabolism-improving reagent comprising whey protein hydrolysate as the active ingredient with the following criteria:
- (1) Molecular weight distribution of 10 kDa or less with main peak between 200 Da and 3 kDa
- (2) APL (Average peptide chain length) of 2-8
- (3) Free amino acid content of 20% or less
- (4) Antigenicity of 1/10,000 or less than that of β-lactoglobulin.
A method of improving lipid metabolism, comprising administering whey protein hydrolysate with the following characteristics:
- (i) Molecular weight distribution of 10 kDa or less with main peak between 200 Da and 3 kDa.
- (ii) APL (Average peptide chain length) of 2-8.
- (iii) Free amino acid content of 20% or less.
- (iv) Antigenicity of 1/10,000 or less than that of β-lactoglobulin.
A method of inhibiting accumulation of triglycerides, cholesterol, or phospholipids in the serum characterized in that whey protein hydrolysate with the following characteristics is administered:
- (i) Molecular weight distribution of 10 kDa or less with main peak between 200 Da and 3 kDa.
- (ii) APL (Average peptide chain length) of 2-8.
- (iii) Free amino acid content of 20% or less.
- (iv) Antigenicity of 1/10,000 or less than that of β-lactoglobulin.
A method of preventing and/or treating hyperlipidemia characterized in that whey protein hydrolysate with the following characteristics is administered:
- (i) Molecular weight distribution of 10 kDa or less with main peak between 200 Da and 3 kDa.
- (ii) APL (Average peptide chain length) of 2-8.
- (iii) Free amino acid content of 20% or less.
- (iv) Antigenicity of 1/10,000 or less than that of β-lactoglobulin.
A method of preventing and/or treating obesity characterized in that whey protein hydrolysate with the following characteristics is administered:
- (i) Molecular weight distribution of 10 kDa or less with main peak between 200 Da and 3 kDa.
- (ii) APL (Average peptide chain length) of 2-8.
- (iii) Free amino acid content of 20% or less.
- (iv) Antigenicity of 1/10,000 or less than that of β-lactoglobulin.
Dependencies are inferred from the claim text.